Compare Citius Pharmaceuticals Inc (CTXR) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Indonesia Energy Corporation Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Indonesia Energy Corporation Limited trades at $2.77 (market cap $43.24M). The key difference: Indonesia Energy Corporation Limited is far larger — about 3.2× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 116,953). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Indonesia Energy Corporation Limited for 24 Days on average.
| CTXR | INDO | |
|---|---|---|
Market Cap | $13.62M | $43.24M |
Volume | 132,438 | 116,953 |
Sector | Health | Energy |
52-Week High | $1.82 | $6.74 |
52-Week Low | $0.48 | $2.49 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.79M | $38.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
INDO trades at $2.77, unchanged on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $5.10 million in 2025 on revenue of $2.01 million, reflecting negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with negative profitability and cash burn. Investment potential hinges on successful execution of drilling operations to boost revenue, but risks include sustained losses, high valuation multiples relative to sales, and reliance on financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
